id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2014-D-0622-0006,FDA,FDA-2014-D-0622,"Draft Guidance for Industry on Best Practices in Developing Proprietary
Names for Drugs; Reopening of the Comment Period",Notice,Extension of Comment Period,2014-08-14T04:00:00Z,2014,8,2014-08-14T04:00:00Z,2014-09-16T03:59:59Z,2014-10-16T01:02:12Z,2014-19261,0,0,090000648182216b
FDA-2014-D-0622-0004,FDA,FDA-2014-D-0622,"Request for Extension from Boehringer Ingelheim Pharmaceuticals, Inc. Consumer Health Care Division",Other,Request for Extension,2014-07-10T04:00:00Z,2014,7,2014-07-10T04:00:00Z,,2014-07-10T21:20:35Z,,0,0,090000648176b5bc
FDA-2014-D-0622-0005,FDA,FDA-2014-D-0622,Request for Extension from the Consumer Healthcare Products Association CHPA,Other,Request for Extension,2014-07-10T04:00:00Z,2014,7,2014-07-10T04:00:00Z,,2014-07-10T21:22:00Z,,0,0,090000648176b79b
FDA-2014-D-0622-0003,FDA,FDA-2014-D-0622,Request for Extension from The Procter & Gamble Company,Other,Request for Extension,2014-07-02T04:00:00Z,2014,7,2014-07-02T04:00:00Z,,2014-07-02T16:48:48Z,,0,0,0900006481759fca
FDA-2014-D-0622-0002,FDA,FDA-2014-D-0622,"Draft Guidance for Industry on Best Practices in Developing Proprietary
Names for Drugs",Other,Guidance,2014-05-29T04:00:00Z,2014,5,2014-05-29T04:00:00Z,,2024-11-12T05:26:47Z,,1,0,090000648171c830
FDA-2014-D-0622-0001,FDA,FDA-2014-D-0622,"Draft Guidance for Industry on Best Practices in Developing Proprietary
Names for Drugs; Availability",Notice,Notice of Availability,2014-05-29T04:00:00Z,2014,5,2014-05-29T04:00:00Z,2014-07-29T03:59:59Z,2020-04-26T05:25:02Z,2014-12348,0,0,090000648171bb46